The Medicines Company
Most Recent
Where Stanley Druckenmiller Is Bullish
Last week, Duquesne Family Office, managed by Stanley Druckenmiller, filed its Q3 13F with the SEC. We’ll look at the fund’s top holdings, buys, and sells.
What Alnylam Pharmaceuticals’ Bottom Line Trend Indicates
Alnylam Pharmaceuticals’ interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.
Behind Valeant’s Branded Drugs: Other 3Q17 Performances
In 3Q17, Valeant’s (VRX) Arestin reported revenues of $26 million, which was ~7% lower on a YoY (year-over-year) basis and 7% lower quarter-over-quarter.
Vabomere: Major Addition to The Medicines Company’s Portfolio?
On August 29, 2017, the FDA approved The Medicines Company’s (MDCO) Vabomere for treating adulating patients suffering with complicated urinary tract infections.
Inclisiran: Long-Term Growth Driver for The Medicines Company?
According to a Monte Carlo simulation performed at Harvard, it’s estimated that 5.0 million patients in the United States stand to benefit from PCSK9 inhibitor therapy.
Small-Caps Are Topping the IBB Portfolio
Biotech stocks and ETFs had a good day on December 21 and rose marginally. The iShares Nasdaq Biotechnology ETF (IBB) rose 0.2% for the day and closed at $332.13.
